Clinical trials: Squamous Non-small Cell Lung Cancer
Lung Squamous Cell Carcinoma
A Study of 7MW3711 Compared With Docetaxel in Advanced Squamous NSCLC After Prior Chemoimmunotherapy
To compare the efficacy and safety of 7MW3711 versus docetaxel in patients with locally advanced or metastatic squamous non-small cell lung cancer (sqNSCLC) .
- Trial name
- NCT07831863
- Testing
- 7MW3711, Docetaxel
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Non-Squamous Non-Small Cell Lung Cancer
A Study of First or Second Line Treatment With Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer
This single arm study will assess the safety and efficacy of Tarceva monotherapy in patients with advanced non-small cell lung cancer. Patients will receive Tarceva 150mg p.o. daily.
- Trial name
- NCT01066884
- Testing
- erlotinib [Tarceva]
- Where
- 2 sites in Russia
- Volunteers
- 5 people
- Sponsor
- Hoffmann-La Roche
Advanced Non-squamous Non-small Cell Lung Cancer
A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab in the Treatment of First-line Non-squamous Non-small Cell Lung Cancer(NSCLC).
This is Phase 3, randomized, open-label, parallel controlled study designed to compare the efficacy and safety of TQB2450 in combination with platinum-containing chemotherapy followed by TQB2450 plus Anlotinib versus tislelizumab…
- Trial name
- NCT05346952
- Testing
- TQB2450 injection, Tilelizumab injection, Anlotinib hydrochloride capsule, Pemetrexed disodium injection, Carboplatin injection
- Where
- China
- Volunteers
- 390 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Castrate-resistant Prostate Cancer CRPC, Squamous Non-Small Cell Lung Cancer sqNSCLC
AZD8186 First Time In Patient Ascending Dose Study
This is a phase I, open-label, multicentre study of AZD8186 administered orally in patients with advanced castrate-resistant prostate cancer (CRPC), squamous non-small cell lung cancer (sqNSCLC), triple negative breast cancer…
- Conditions
- Advanced Castrate-resistant Prostate Cancer CRPC, Squamous Non-Small Cell Lung Cancer sqNSCLC, Triple Negative Breast Cancer TNBC
- Trial name
- NCT01884285
- Testing
- Part A: AZD8186 monotherapy, Part B: AZD8186 monotherapy, Part C1: Abiraterone acetate combination with AZD8186
- Where
- 13 sites in United States, Canada and 2 more
- Volunteers
- 147 people
- Sponsor
- AstraZeneca
Endometrial Cancer, Ovarian Cancer
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
HWK-007-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-007, a protein tyrosine kinase 7 (PTK7)-targeted antibody drug conjugate (ADC), in adult participants with advanced or metastatic solid…
- Conditions
- Endometrial Cancer, Ovarian Cancer, Ovarian Cancer Metastatic, Ovarian Cancer Metastatic Recurrent
- Trial name
- NCT07444814
- Testing
- HWK-007
- Where
- 12 sites in United States
- Volunteers
- 226 people
- Sponsor
- Whitehawk Therapeutics, Inc.
NSCLC (Non-small Cell Lung Cancer), HNSCC
A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects with Select Advanced Solid Tumors.
- Conditions
- NSCLC (Non-small Cell Lung Cancer), HNSCC, Endometrial, Ovarian Cancer
- Trial name
- NCT07814248
- Testing
- TS-104
- Where
- 3 sites in United States
- Volunteers
- 74 people
- Sponsor
- TwoStep Therapeutics, Inc.
Carcinoma, Non-Small-Cell Lung
MYLUNG Consortium Study Protocol 2
This pragmatic study looks to quantify the testing timeline, operational barriers, and outcomes of biomarker-guided therapy in a large, community-based, and largely unselected patient population with early stage and advanced…
- Trial name
- MYLUNG (NCT05644808)
- Where
- 18 sites in United States
- Volunteers
- 1,002 people
- Sponsor
- US Oncology Research
Non-Squamous Non-Small Cell Lung Cancer
An Observational Study of Avastin (Bevacizumab) in Elderly Patients With Non-Squamous Non-Small Cell Lung Cancer in Clinical Practice
This prospective, observational study will assess the effectiveness and safety of Avastin (bevacizumab) as 1st line therapy in elderly patients with advanced non-squamous non-small cell lung cancer in clinical practice.
- Trial name
- NCT01893268
- Where
- 88 sites in France
- Volunteers
- 279 people
- Sponsor
- Hoffmann-La Roche
Non Small Cell Lung Cancer (Squamous or Non Squamous), Stage 4 NSCLC
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
This is a study to evaluate the safety and efficacy of EIK1001 administered intravenously in combination with pembrolizumab and histologically appropriate chemotherapy for patients with stage 4 NSCLC.
- Trial name
- TeLuRide-008 (NCT07365319)
- Testing
- EIK1001, Pembrolizumab (KEYTRUDA®), Paclitaxel + Carboplatin
- Where
- 32 sites in United States, Australia and 7 more
- Volunteers
- 750 people
- Sponsor
- Eikon Therapeutics
Non-Small Cell Lung Cancer
Real-Life Study With Nivolumab (BMS-936558) in Advanced NSCLC Patients After Prior Chemotherapy
This study intends to describe the real-life effectiveness and safety of nivolumab in advanced NSCLC patients in Germany, as well as the patient profile, pattern of use and the quality of life.
- Trial name
- ENLARGE-Lung (NCT02910999)
- Where
- Germany
- Volunteers
- 868 people
- Sponsor
- Bristol-Myers Squibb
PDL1 Gene Mutation, Non Small Cell Lung Cancer
177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors
This is a Phase 0/1, First-in-Human (FIH), study to evaluate safety, tolerability of 177Lu-RAD204 in participants with selected solid tumors, and to determine the MTD and/or recommended dose for future exploration.
- Conditions
- PDL1 Gene Mutation, Non Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), TNBC, Triple Negative Breast Cancer
- Trial name
- NCT06305962
- Testing
- 177Lu-RAD204
- Where
- 6 sites in Australia
- Volunteers
- 30 people
- Sponsor
- Radiopharm Theranostics, Ltd
HER2 Positive Gastric Cancer, Colorectal Cancer
FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors
This is a Phase 1, single-dose, open-label, dose-escalation study. The study will be conducted in three parts (i.e. regimens) in an outpatient setting as follows: Regimen A: FATE-NK100 as a monotherapy in subjects with advanced…
- Conditions
- HER2 Positive Gastric Cancer, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, EGFR Positive Solid Tumor
- Trial name
- NCT03319459
- Testing
- FATE-NK100, Cetuximab, Trastuzumab
- Where
- 4 sites in United States
- Volunteers
- 44 people
- Sponsor
- Fate Therapeutics
Non Small Cell Lung Carcinoma, c-MET
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Non small cell lung carcinoma (NSCLC) is the most frequently occurring histologic subtype of lung cancer and is the leading cause of cancer-related deaths worldwide.
- Trial name
- NCT06772623
- Testing
- Telisotuzumab Adizutecan, Budigalimab, Pembrolizumab
- Where
- 127 sites in United States, Argentina and 15 more
- Volunteers
- 252 people
- Sponsor
- AbbVie
Non-small Cell Lung Cancer
mil60 Versus Bevacizumab in Patients With Treatment-naïve Non-squamous Non-small Cell Lung Cancer
This randomized, double-blind, multi-center phase 3 study is aimed to compare the efficacy and safety of mil60 with bevacizumab as first-line treatment when combined with standard chemotherapy (paclitaxel/carboplatin) in…
- Trial name
- NCT03196986
- Testing
- mil60, Bevacizumab
- Where
- 2 sites in China
- Volunteers
- 517 people
- Sponsor
- Beijing Mabworks Biotech Co., Ltd.
Adenocarcinoma Lung Cancer; Squamous Cell Lung Carcinoma
A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer
The purpose of this study was to evaluate the anti-tumor activity of single agent BYL719, INC280, LDK378 and MEK162 in advanced NSCLC patients carrying specific molecular alterations.
- Trial name
- NCT02276027
- Testing
- BYL719, INC280, LDK378
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Non-squamous Non-small-cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer
JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
This Phase 3 study will evaluate the efficacy of JAB-21822+JAB-3312 versus tislelizumab (PD-1 Ab) combined with pemetrexed+carboplatin as the first line treatment in subjects with KRAS G12C mutated locally advanced or metastatic…
- Trial name
- NCT06416410
- Testing
- JAB-21822, Tislelizumab, JAB-3312
- Where
- 37 sites in China
- Volunteers
- 392 people
- Sponsor
- Allist Pharmaceuticals, Inc.
Metastatic Colorectal Cancer, Metastatic Cervical Cancer
Safety of Effivia®, a Bevacizumab Biosimilar
This is a post-marketing observational study aimed to evaluated the safety profile of Effivia®, a biosimilar of bevacizumab, in mexican patients with different types of cancer.
- Conditions
- Metastatic Colorectal Cancer, Metastatic Cervical Cancer, Non Squamous Non Small Cell Lung Cancer
- Trial name
- NCT06313268
- Testing
- Bevacizumab Biosimilar MB02
- Where
- 5 sites in Mexico
- Volunteers
- 83 people
- Sponsor
- Laboratorios Liomont
NSCLC (Advanced Non-small Cell Lung Cancer), HNSCC
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
A Phase 1, First in Human, Open-Label Multicenter Study to Evaluate ALX2004, an Antibody Drug Conjugate Targeting EGFR in Participants with Advanced or Metastatic Select Solid Tumors
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer), HNSCC, CRC (Colorectal Cancer), ESCC
- Trial name
- NCT07085091
- Testing
- ALX2004
- Where
- 12 sites in United States
- Volunteers
- 170 people
- Sponsor
- ALX Oncology Inc.
Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
This is a phase 1 dose escalation trial of ZM008, an anti-LLT1 antibody as a single agent followed by combination with Toripalimab in patients with advanced solid tumors who have exhausted all standard therapy available or are…
- Conditions
- Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Pancreas Adenocarcinoma, Biliary Tract Cancer
- Trial name
- NCT06451497
- Testing
- ZM008
- Where
- 3 sites in United States
- Volunteers
- 100 people
- Sponsor
- Zumutor Biologics Inc.
Advanced Solid Tumors, Non-Small Cell Lung Cancer
A Study of IOV-5001 in Adults With Advanced Solid Tumors
A Phase 1/2, multicenter, multi-cohort, open-label study of an autologous tumor-infiltrating lymphocytes (TIL) regimen with IOV-5001 in participants with previously treated advanced solid tumors
- Conditions
- Advanced Solid Tumors, Non-Small Cell Lung Cancer, Triple Negative Breast Cancer (TNBC), Colorectal Cancer
- Trial name
- NCT07743723
- Testing
- IOV-5001
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- Iovance Biotherapeutics, Inc.